Clinical Study to Evaluate Efficacy and Safety of ANT-301 in Patients With Knee Osteoarthritis in Grade III/IV by K/L

Study Design: open-label, single-center, dose-escalation study

Inclusion criteria

• Patients who have been provided with information about the clinical trial and have provided written consent on the informed consent form
• Patients aged 19 to 70 years old.
• Patients diagnosed with K&L grade III/IV knee osteoarthritis
• Patients with a VAS pain score of 40mm or higher when measured on a 100-point scale

Exclusion criteria

• Patients with joint diseases other than osteoarthritis
• Patients who have undergone knee joint surgery or radiation therapy to the knee joint within 6 months prior to the screening
• Patients who received intra-articular injections within 6 months prior to the screening
• Patients who have received systemic steroid therapy within 3 months prior to the screening
• Patients who have received immunosuppressive agents within 3 months prior to the screening
• Patients who have received cell therapy or gene therapy to the target knee within 5 years prior to the screening
• Patients who are unwilling to use contraception during the clinical trial period